Loading...
BioHarvest Sciences Inc.
CNVCF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$6.30
$0.00(0.00%)

The company's financials show resilient growth, with revenue advancing from $4.52M in Q4 2023 to $6.54M in Q3 2024. Gross profit remained healthy with margins at 57% in Q3 2024 compared to 51% in Q4 2023. Operating income hit -$2.10M last quarter, sustaining a consistent -32% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$1.75M. Net income dropped to -$2.69M, while earnings per share reached $0.00. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan